Tracer library / [211At]At-211-AMT
[211At]At-211-AMT
Also written as At-211-AMT
- Radionuclide
- At-211 t½ 431 min
- Modality
- Therapy
- Production route
- —
- Stage
- Preclinical
- Syntheses indexed
- 0
What it is
- Compound class
- radiolabeled amino acid analog (alpha-methyltyrosine/alpha-methylphenylalanine derivative)
- Target / mechanism
- L-type amino acid transporter 1 (LAT1) PMID 32916470
- Clinical application
- Targeted alpha-radionuclide therapy for LAT1-positive cancers, including melanoma PMID 3352274
- Theranostic pair
- [11C]AMT
Published syntheses
No synthesis has been parsed for this agent yet.
Need this precursor?We can point you to suppliers for [211At]At-211-AMT, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 1 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Diagnostic pair signal at discovery: YES - C-11. Compound class inferred from precursor name (not stated outright) -- PMID 32916470: '2-[211At]AAMP was prepared from the stannyl precursor.'. Stage set/updated at stage 39 from PMID 32916470: 'Preclinical evaluation of new α-radionuclide therapy targeting LAT1: 2-[211At]astato-α-methyl-L-phenylalanine in tumor-bearing model.'.